Privately held biotechnology innovator Mentari Therapeutics has entered into a definitive, all-stock merger agreement with InMed Pharmaceuticals (NASDAQ: INM). The strategic transaction combines Mentari’s specialized migraine pipeline with InMed’s established public market framework, aiming to accelerate clinical options for individuals managing migraines — a debilitating neurological disorder impacting over 1 billion people worldwide. Upon completion of the regulatory process in the second half of 2026, the unified business will operate under the name Mentari Therapeutics, Inc. and debut on the Nasdaq Capital Market under a newly designated trading ticker.
Concurrently, an oversubscribed private placement has secured approximately $290 million in gross proceeds. The financing round was anchored by Fairmount, with institutional backing from prominent investment managers including Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock, Wellington Management, TCGX, Blackstone, BB Biotech, Farallon, RTW, Vivo, and Perceptive Advisors. This significant capital reserve is projected to extend the combined firm’s operational runway through 2028, funding operations past the anticipated release of pivotal data readouts from its parallel pipeline.
-
MT-001: An anti-PACAP monoclonal antibody, with first-in-human regulatory filings scheduled for mid-2026 and Phase 2a proof-of-concept readouts targeted for 2028.
-
MT-002: A potential first-in-class bispecific antibody designed to neutralize both CGRP and PACAP biological pathways, with regulatory filings slated for Q1 2027 and initial Phase 1 data in healthy subject cohorts expected later that year.
This multi-pathway inhibition strategy addresses a substantial therapeutic gap: currently, 40% to 50% of patients do not secure a 50% reduction in monthly migraine days using standard approved treatments. Preclinical evaluations orchestrated by Paragon Therapeutics demonstrate that both MT-001 and MT-002 hold equal or superior in vitro potency compared to baseline benchmark antibodies, coupled with pharmacokinetic metrics in non-human primates that support convenient subcutaneous self-administration in humans.
Based on agreed transaction parameters, pre-merger InMed shareholders are modeled to retain an estimated 1.51% equity stake in the consolidated business, reflecting a pro forma equity valuation of roughly $421.4 million inclusive of the parallel private placement. This baseline ownership allocation remains subject to adjustment depending on InMed’s verified net cash balances immediately prior to the closing threshold. Additionally, existing InMed equity holders will receive contingent value rights linked to potential cash proceeds from any post-closing monetization or licensing deals involving InMed’s legacy small-molecule research assets. Following the transaction’s close, Julie Bruno, Growth Partner at Fairmount, will assume the role of Chair for the integrated board of directors.